Several possible studies
Story checked
New investigational drug delivers up to 23.3% weight loss in people with obesity and diabetes (opens in a new tab)
medicalxpress.com · 2026-09-30
Short answer
Several possible studiesNo clear answer.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
New investigational drug delivers up to 23.3% weight loss in people with obesity and diabetes
medicalxpress.com · 2026-09-30
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 4Not checkedNew data from a phase 2b study being presented at the 2026 annual meeting of the European Association for the Study of Diabetes show that, for people living with obesity and type 2 diabetes, treatment with Eli Lilly's investigational medication EloraTZP, a combination of eloralintide and tirzepatide, resulted in weight loss of up to 23.3% at the maximum dose and substantial improvements in blood sugar control.View evidenceHide evidence
As statedup to 23.3% weight loss
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 4Not checkedThe study evaluated the safety and efficacy of eloralintide in combination with tirzepatide in 367 adults with obesity or overweight and type 2 diabetes.View evidenceHide evidence
As stated367 adults
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 4Not checkedAt 48 weeks, all four dosing combinations of eloraTZP met the primary and secondary endpoints, delivering substantial weight loss and reductions in glycated hemoglobin (HbA1c).View evidenceHide evidence
As stated48 weeks; all four dosing combinations
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 4Not checkedAt the highest dose, the mean weight loss was 23.3% and the average decrease in HbA1c was 2.9%; the most common adverse events were gastrointestinal and generally mild or moderate, occurring primarily during dose escalation.View evidenceHide evidence
As stated23.3% weight loss; 2.9% HbA1c decrease
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Crossref, Europe PMC · 15 candidate papers
New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders · 2026 · PubMed
Review for "HbA1c reduction with tirzepatide in people with type 2 diabetes: The contribution of weight loss assessed by a mediation analysis"
2025 · Crossref
Future Directions in the Medical Treatment of Obesity: A Narrative Review.
2026 · Europe PMC
Cardiometabolic Risk Reduction Through Selective Amylin Receptor Agonism: Emerging Cardiovascular Implications of Eloralintide.
Cardiology in Review · 2026 · PubMed
Type 1 diabetes in the era of obesity: Pathophysiology and therapeutic implications.
2026 · Europe PMC
And 10 more candidates considered.